Evidence map›Paper›PMID 33247799›Full record

ArticleBreast cancer research and treatment2021

Similar rates of residual disease in patients with DCIS within 2 mm of lumpectomy margin regardless of the presence of invasive carcinoma.

Bridget N Kelly, Olga Kantor, Rong Tang, Suzanne B Coopey, Barbara L Smith, Conor R Lanahan, Jenna E Korotkin, Michelle C Specht

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Bridget N KellyDivision of Surgical Oncology, Massachusetts General Hospital, Yawkey 7, 55 Fruit Street, Boston, MA, 02114, USA.
Olga KantorDivision of Surgical Oncology, Massachusetts General Hospital, Yawkey 7, 55 Fruit Street, Boston, MA, 02114, USA.
Rong TangDivision of Surgical Oncology, Massachusetts General Hospital, Yawkey 7, 55 Fruit Street, Boston, MA, 02114, USA.
Suzanne B CoopeyDivision of Surgical Oncology, Massachusetts General Hospital, Yawkey 7, 55 Fruit Street, Boston, MA, 02114, USA.
Barbara L SmithDivision of Surgical Oncology, Massachusetts General Hospital, Yawkey 7, 55 Fruit Street, Boston, MA, 02114, USA.
Conor R LanahanDivision of Surgical Oncology, Massachusetts General Hospital, Yawkey 7, 55 Fruit Street, Boston, MA, 02114, USA.
Jenna E KorotkinDivision of Surgical Oncology, Massachusetts General Hospital, Yawkey 7, 55 Fruit Street, Boston, MA, 02114, USA.
Michelle C SpechtDivision of Surgical Oncology, Massachusetts General Hospital, Yawkey 7, 55 Fruit Street, Boston, MA, 02114, USA. mspecht@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-0456-348X
Massachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe 2014 Society of Surgical Oncology/American Society for Radiation Oncology (SSO/ASTRO) breast-conserving surgery (BCS) margin guidelines for invasive cancer recommended "no ink on tumor" as an adequate margin width. However, 2016 SSO/ASTRO margin guidelines for pure DCIS recommended a 2 mm margin. Thus, management of a margin with DCIS > 0 mm but < 2 mm differs based on presence or absence of invasive carcinoma. We compared rates of residual disease in patients with pure DCIS to patients with invasive cancer with DCIS.

methodsBCS with complete shaved cavity margins (SCM) for invasive carcinoma or pure DCIS from 2004 to 2006 at our institution was reviewed. Margin width was measured on the main specimen and the presence of carcinoma in the SCM was used as a surrogate for residual disease in the cavity. Rates of residual disease were determined for varying margin widths of invasive carcinoma and DCIS.

resultsOf 329 BCS patients, 123 (37%) patients had pure DCIS and 206 (63%) had invasive cancer with DCIS. In the pure DCIS cohort, 61 patients had DCIS between 0 and 2 mm from the inked margin; 32 (52%) of which had residual disease in the SCM. In the invasive cancer plus DCIS cohort, 92 had DCIS between 0 and 2 mm from the inked margin; 39 (42%) of which had residual disease in the SCM (p = 0.221).

conclusionRates of residual disease are similar in patients treated with lumpectomy for pure DCIS and those with invasive carcinoma with DCIS when DCIS is found between 0 and 2 mm from the inked margin.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingFemaleHumansMargins of ExcisionMastectomy, SegmentalNeoplasm, ResidualBreast-conserving surgeryMarginsMargin widthResidual disease

Identifiers

PMID33247799
OpenAlexW3107694806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.